To develop, manufacture and conduct clinical testing of a novel nanoparticle displaying a SARS-CoV2 vaccine co-administered with a novel adjuvant.
- Funded by Gates Foundation
- Total publications:0 publications
Grant number: INV-022092
Grant search
Key facts
Disease
COVID-19Start & end year
2020Known Financial Commitments (USD)
$9,999,899Funder
Gates FoundationResearch Location
United States of AmericaLead Research Institution
Icosavax, Inc.Research Priority Alignment
N/A
Research Category
Vaccines research, development and implementationResearch Subcategory
N/ASpecial Interest Tags
N/AStudy Type
ClinicalClinical Trial Details
UnspecifiedBroad Policy Alignment
PendingAge Group
UnspecifiedVulnerable Population
UnspecifiedOccupations of Interest
Unspecified
Abstract
N/A